Gut Bacteria May Trigger Parkinson's Disease Before Brain Symptoms Appear

This review challenges the traditional brain-centric view of Parkinson's disease, proposing instead that the condition may originate in the gut microbiome years before motor symptoms appear. The authors synthesize evidence supporting a gut-first model where microbiome dysbiosis triggers intestinal inflammation and barrier dysfunction, enabling alpha-synuclein protein aggregation to spread from the enteric nervous system to the brain via the vagus nerve.

The review highlights that non-motor symptoms like constipation and gastrointestinal complaints affect 80% of Parkinson's patients and often precede motor symptoms by decades. Individuals with inflammatory bowel diseases show elevated Parkinson's risk, while anti-inflammatory treatments can reduce this risk. Critically, people with REM sleep behavior disorder (RBD) have a 73.5% chance of developing Parkinson's within 12 years and may represent a distinct gut-first subtype characterized by early autonomic dysfunction.

The evidence includes detection of alpha-synuclein aggregates in the gastrointestinal tract up to 20 years before diagnosis, though this remains controversial. Epidemiological studies show mixed results regarding whether vagotomy (surgical cutting of the vagus nerve) protects against Parkinson's, with full truncal vagotomy showing protective effects while selective procedures do not.

This paradigm shift has profound therapeutic implications. If Parkinson's begins in the gut, interventions targeting the microbiome—including probiotics, prebiotics, fecal microbiota transplants, and anti-inflammatory treatments—could prevent or delay disease progression during the critical prodromal phase. The gut-first model offers hope for earlier detection through gut-based biomarkers and novel prevention strategies that could transform Parkinson's from a progressive neurodegenerative disease into a preventable condition.